Daniel Lang, a partner in Goodwin’s Technology Companies + Life Sciences Group, concentrates on startup, financing, M&A, general corporate and securities law matters, and has significant experience in company formations; seed, venture and growth financings; mergers and acquisitions; IPOs and other capital markets transactions; SEC compliance and corporate governance. Mr. Lang represents public and private companies in diverse industries such as e-commerce, digital media, advertising technology, marketplace lending, consumer and enterprise software, healthcare, health technology, biotechnology and diagnostics, as well as the investors and financial services firms that focus on these companies. He has experience advising companies through every stage of the corporate life cycle – from entity selection and initial financing through successful initial public offering or acquisition.

Mr. Lang was recognized as a New York Metro Rising Star by Super Lawyers in 2014-2017.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Mr. Lang’s representative clients include public companies: Foundation Medicine, Ocera Therapeutics, Chiasma, Allena Pharmaceuticals and Precipio, as well as private companies: Glossier, Hubble Contacts, Thrive Global, Landover Wireless, LifeCo, Noteworth, Paperless Post, Pond5, Aircall, Celtra, Orchard, Megaphone TV, Proclivity Media, Zive, Codiak BioSciences, Oculus Health, Precision Biologics, Syntimmune, TARA Biosystems, EpicentRx and Linkwell Health.

Representative Matters

REFERENZMANDATE

代表事项

Public Company Transactions
  • Ocera Therapeutics, in its acquisition by Mallickrodt for up to $117 million in upfront cash and contingent (CVR) consideration 
  • Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, in its $75 million initial public offering on the NASDAQ Stock Market
  • Chiasma, a late-stage biopharmaceutical company, in its $102 million initial public offering on the NASDAQ Stock Market
  • J.P. Morgan and Barclays Capital in the $184 million initial public offering of Intrexon Corporation, a synthetic biology company, on the NYSE
  • J.P. Morgan and BofA Merrill Lynch in the $116 million follow-on offering of Intrexon Corporation
  • JMP Securities in the $230 million follow-on offering of Intrexon Corporation
  • Cantor Fitzgerald in a $200 million “at the market” offering facility for Intrexon Corporation
  • Foundation Medicine, a cancer diagnostics company, in (i) its $120 million initial public offering on the NASDAQ Stock Market and (ii) its collaboration agreement and equity transaction with Roche, total value in excess of $1 billion
  • Ocera Therapeutics, a biotechnology company, in its $28 million PIPE financing, $25 million public offering and $25 million “at the market” offering facility
  • Vivo Capital in its participation in a $12.5 million unit offering of BioPharmX
  • Vivo Capital, as lead investor, in a $35 million financing of Strongbridge Pharma
M + A
  • Glossier in its acquisition of Dynamo E-Media 
  • Represented Thar Pharmaceuticals, a biopharmaceutical company, in its acquisition by an affiliate of The Grünenthal Group
  • Songza, a streaming music company, in its sale to Google
  • M5 Networks, a cloud communications company, in its $146 million acquisition by ShorTel
  • XGraph, a social targeting company, in its acquisition by Add This (formerly Clearspring)
  • Fidelis Security Systems, a cybersecurity company, in its acquisition by General Dynamics
  • Nomi Technologies, a retail technology company, in its acquisition by Brickstream Corporation
  • Represented Tagman, the pioneer tag management and attribution company, in its acquisition by Ensighten
Private Financings
  • Glossier in its $52 million financing led by Institutional Venture Partners and Index Ventures 
  • Codiak BioSciences in its $76.5 million financing with participation by ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, and Alexandria Venture Investments, Qatar Investment Authority, Boxer Capital of the Tavistock Group, Sirona Capital, EcoR1 Capital and Casdin Capital
  • Hermed Capital in its investments in Prognos and Spineology
  • Celtra in its $15.0 million financing by affiliates of WPP and Unilever
  • Syntimmune in its $50.0 million financing led by Apple Tree Partners
  • Glasswing Ventures as lead investor in an $8.3 million financing of Talla
  • PatientBank in its $2.2 million financing led by General Catalyst and Khosla Ventures with participation by SV Angels, Spectrum 28 and Data Collective
  • Hubble Contacts in its $16.5 million financing led by First Mark Capital, Greycroft, Two River and Wildcat Capital Management 
  • Glossier in its $24 million Series B financing led by Institutional Venture Partners, with participation from Index Ventures, Thrive Capital and Forerunner Ventures
  • Hubble Contacts in $7.2 million seed financings backed by Wildcat Capital Management, Two River, Founders Fund and Greycroft Partners
  • Aircall.io in its $8 million financing led by Baldteron Capital
  • Allena Pharmaceuticals in its $53 million Series C financing led by Partner Fund Management, Fidelity and Wellington
  • Codiak BioSciences in its $80 million financing led by Arch Venture Partners and Flagship Ventures
  • InterWest and Orbimed, as lead investors, in a $32 million investment round of Avedro
  • HYPR Brands in its $5 million financing led by Silvertech Ventures, Edgewater Equity and a number of other strategic investors.
  • Precision Biologics in its $50 million financing by an affiliate of NantWorks
  • Orchard Platform in its $30 million financing led by Thrive Capital, Spark Capital and Canaan Partners
  • Even Financial in its $2.8 million financing led by Canaan Partners and Lerer Hippeau Ventures
  • Into the Gloss (d/b/a Glossier) in its $8.4 million financing led by Thrive Capital
  • Pond5 in its $61 million financing by Accel Partners and Stripes Group
  • Paperless Post in its $25 million financing led by August Capital
  • Megaphone TV in its $4.3 million financing led by Softbank Korea
  • Nomi Technologies in its $10 million financing by Accel Partners, First Round Capital, Greycroft Partners and Forerunner
Professional Activities

Mr. Lang is a frequent lecturer at the Cardozo Tech Law Start Up Clinic, Columbia Business School, Columbia Law School, Cornell Tech and eLab NYC on venture financings and other elements of start-up law.

Professional Experience

Prior to joining Goodwin, Mr. Lang was an associate in the New York office of Heller Ehrman.

Recognition

Mr. Lang was named a New York Metro Rising Star by Super Lawyers in 2014-2017. In law school, Mr. Lang was an articles editor of the Cardozo Law Review.

In The News

MELDUNGEN

ACTUALITÉS

在新闻中

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2006
Benjamin N. Cardozo School of Law

(cum laude)

B.A., 2003
Tufts University

(magna cum laude)

Admissions

Bar

New York
New Jersey
Get In Touch
German Translation
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师